Open Innovation Portal
DNDi’s mission is to develop safe, effective, and affordable new treatments for patients suffering from neglected diseases and to ensure equitable access to these. Encouraging innovation is one way that we do this. Dedicated to fostering advancement in global health by supporting the research community in the field of neglected diseases, we have taken steps to disseminate the scientific knowledge gained through research projects with our many partners. This will be done through both the more traditional means of scientific articles, and less traditional means, notably by sharing data on chemical compounds in the public domain.
The data we make available is the fruit of collaboration with our partners and is part of our constant effort to render accessible to entire scientific community, whenever possible:
- Both positive and negative research results, as negative results can offer a wealth of information, allow for new research approaches to the same series with potentially different outcomes, and eliminate duplication of efforts
- Data that DNDi and its partners have willfully agreed to place in the public domain, free of any and all IP constraints.
For more information: “Striving for increasingly open innovation models”
The Open Synthesis Network is a collaborative project that aims to engage master’s and undergraduate students in research for neglected diseases. Students from ten universities are working on compounds that kill leishmania donovani and leishmania infantum, the parasites that cause visceral leishmaniasis. More
AMG Consultants has produced guides to share free solutions to common problems faced by medicinal and computational chemists in not-for-profit research. More
The NTD Drug Discovery Booster aims to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease. The project brings together DNDi and seven pharmaceutical companies: Abbvie, AstraZeneca plc, Celgene Corporation, Eisai Co Ltd, Merck, Shionogi & Co Ltd, and Takeda Pharmaceutical Ltd. More
Leishmania Mechanism of Action Consortium
The Leishmania Mechanism of Action Consortium is a collaborative project that aims to engage leading academic labs to unravel the way key DNDi leishmanial candidates tackle parasites.
The Pandemic Response Box (PRB)
The Pandemic Response Box (PRB) is a collection of 400 known antibacterial and antiviral compounds for use in first-line screening against emerging pandemic pathogens.
DNDi identified an interesting new hit compound active against Leishmania donovani from an innovative screening collaboration with Pfizer.
The Pathogen Box will contain ~400 diverse, drug-like molecules active against neglected diseases of interest and will be available free of charge at the end of 2015.
This new screening cascade was used to screen a compound collection named the Diversity Oriented Synthesis (DOS) Informer Set (9,907 compounds) and led to the identification of two new chemical series with antileishmanial activity.
A set of 100 registered drugs with drug repositioning potential for neglected tropical diseases was assembled. The compound collection was systematically screened against protozoan parasites, T. b. rhodesiense, L. donovani, T. cruzi and P. falciparum.
In late 2013, DNDi and colleagues published an analysis in The Lancet Global Health looking at the R&D landscape over the last decade in terms of new therapeutic products for 49 so-called neglected diseases. In the hope of promoting further research, we have created a public data-sharing page with full datasets from the study freely accessible to all.
Screening of the MMV Open Access Malaria Box in the search for new drugs against Human African Trypanosomiasis (HAT), visceral leishmaniasis and Chagas disease
iNTRODB is an integrated system for searching drug-target proteins from parasitic protozoa genomes that cause neglected tropical diseases, including leishmaniasis, Chagas’ disease and human African trypanosomiasis
We have evaluated multiple hits generated from a high-throughput screen of over 300,000 compounds to identify inhibitors of T. cruzi. These studies have resulted in the discovery of two novel series currently in lead optimisation.
This second release includes data on a further 84 compounds from the two more advanced series of fenarimols which include the preclinical candidates EPL-BS0967 and EPL-BS1246, both of which are T.cruzi CYP51 inhibitors.
Identification of compounds against Trypanosoma brucei brucei BS427 by high-throughput screening of whole parasites (87,926 compounds)
Screening and optimization of specific chemical series against Human African Trypanosomiasis (HAT): 4926 compounds
For more information: email@example.com